VivoSeq
Infectious Disease

Smallpox

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Smallpox is an early-stage landscape with 0 programs across 3 companies. The most active players are Sanofi, Bristol-Myers Squibb, Emergent BioSolutions.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalEmergent BioSolutions logo

Emergent BioSolutions

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Withdrawn2 · 13%
Terminated1 · 7%
Active, not recruiting1 · 7%
Available1 · 7%

Clinical Trials

Trial Activity

15 trials

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo
Active, not recruiting·Centers for Disease Control and Prevention·Phase 3·NCT02977715·1,600 enrolled
Dressing Preparations for Smallpox
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00063856·102 enrolled
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT00002261
A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00026611
Phase I Trial of Smallpox Vaccine
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00046397·195 enrolled
Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00053742·80 enrolled
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
Completed·—·Phase 3·NCT03699124·1,129 enrolled
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
Completed·—·Phase 2·NCT01668537·651 enrolled
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
Completed·Emergent BioSolutions logoEmergent BioSolutions·Phase 2·NCT00053482·357 enrolled
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
Completed·Sanofi logoSanofi·Phase 2·NCT00258947·230 enrolled
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
Completed·—·Phase 3·NCT01913353·440 enrolled
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
Terminated·Sanofi logoSanofi·Phase 1·NCT00282581·2 enrolled
SIGA-246 to Treat Smallpox
Withdrawn·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00303225
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
Withdrawn·SSIGA Technologies·N/A·NCT03972111
Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses
Available·UU.S. Army Medical Research and Development Command·N/A·NCT02080767

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)